Latest Regulatory News

EDU Holdings Limited is set to renew its on-market share buyback program, aiming to repurchase up to 14.4 million shares over the next year, continuing its strategy to enhance shareholder value.

European Lithium Limited updates investors on the expiry of 208 million options and outlines plans for issuing replacement options pending shareholder approval.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for a suite of Australian iShares ETFs, outlining key dates and options for reinvestment. Investors are reminded to complete necessary tax certifications ahead of the record date.

Duxton Farms has disclosed the indicative results of shareholder elections for its proposed merger with four agribusiness companies, setting the stage for a decisive vote next month.

Aurumin Limited has secured Supreme Court approval to convene shareholder and optionholder meetings for Brightstar Resources’ proposed full acquisition. The company’s directors unanimously back the schemes, setting the stage for a pivotal vote in November.

Dundas Minerals has raised $1.1 million through a discounted share placement to fund ongoing gold exploration in Western Australia, alongside appointing a new Company Secretary to strengthen corporate governance.

Imperial Pacific Limited has announced its Dividend Reinvestment Plan (DRP) issue price for 2025 at $1.85 per new share, maintaining parity with current trading levels and foregoing any discount. New shares will be issued within two weeks, aligning with existing shares.

Hastings Technology Metals has responded to an ASX price query, denying any undisclosed information behind its recent share price and volume spike, citing recent joint venture and asset sale announcements as likely drivers.

Johns Lyng Group shareholders have overwhelmingly approved a scheme of arrangement for acquisition by Pacific Equity Partners, pending final court approval.

NH3 Clean Energy updates investors on the WAH2 clean ammonia project, highlighting strong market potential, strategic partnerships, and robust project economics as it moves toward a Final Investment Decision.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Anatara Lifesciences has completed the first tranche of its two-part share placement, issuing over 33 million ordinary shares to professional investors. This move marks a significant step in the company’s capital raising efforts amid ongoing product development.